This Plain Language Summary of Publication article (PLSP) from Future Oncology describes the DESTINY-Lung02 study, which tested trastuzumab deruxtecan (T-DXd) in 152 adults with HER2-mutant metastatic non-small-cell lung cancer who had previously received standard treatments. Researchers evaluated two different doses of T-DXd to assess effectiveness and safety, though the study wasn’t designed to compare the doses directly.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial’ and was published in the Journal of Clinical Oncology.

Visit ASCO using the link to read the original article.